View profile

FarmaKology Newsletter - Issue #29

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


February 4 · Issue #29 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “”, and happy to have you featured on our newsletter (+1950 Subscribers ) !

Today's Startup
Bluedrop Medical
Bluedrop Medical are developing a system to reduce the burden of diabetic foot ulcers.There are currently almost half a billion diabetics worldwide and it has been estimated that up to 25% will develop a foot ulcer at some point in their life. Of the millions who develop ulcers worldwide every year, hundreds of thousands will require amputation due to infection. Bluedrop Medical are combining detection technology with the internet of things, to create a connected health system capable of identifying ulcers early, where they can be treated more effectively and cheaply.
With 11 coronavirus cases confirmed in the United States, the Wistar Institute is among the leading laboratories working to develop a vaccine for the virus.The Wistar Institute announced its partnership with Inovio Pharmaceuticals to accelerate vaccine development for the recent coronavirus outbreak.
Clovis Oncology, Inc. today announced that Rubraca® (rucaparib) is now available and reimbursed in France. Rubraca® (rucaparib) is an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.
RegeneRx Biopharmaceuticals, Inc.a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that GtreeBNT, its Korean partner in the U.S. for development of RGN-259 for the treatment of dry eye disease, issued an update on the U.S. phase 3 clinical trial. 
Ligand Pharmaceuticals Incorporated announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China. Technologies that have shown potential or general applicability in the antiviral or therapeutic antibody areas include Ligand’s Captisol, OmniAb and LTP (Liver-Targeted Prodrug) platforms.
Research & Study
Antibody Drug Conjugates: Manufacturing Precision Guided Therapeutics by GEN Podcasts | Free Listening on SoundCloud
Job Opportunities
Upcoming Events
Adverse Effects on Mental Health in Younger Patients
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue